Alnylam Pharmaceuticals Short Interest Ratio and Short Volume

Alnylam Pharmaceuticals (NASDAQ:ALNY) Short Interest Frequently Asked Questions

What is Alnylam Pharmaceuticals' current short interest?

Short interest is the volume of Alnylam Pharmaceuticals shares that have been sold short but have not yet been closed out or covered. As of September 30th, investors have sold 4,010,000 shares of ALNY short. Learn More on Alnylam Pharmaceuticals' current short interest.

What is a good short interest ratio for Alnylam Pharmaceuticals?

The short interest ratio, also known as the "days to cover ratio", is calculated by dividing the number of shares of a stock sold short divided by its average trading volume. A short interest ratio ranging between 1 and 4 generally indicates strong positive sentiment about a stock and a lack of short sellers. A short interest ratio of 10 or greater indicates strong pessimism about a stock. Alnylam Pharmaceuticals currently has a short interest ratio of 7.0. Learn More on a good short interest ratio for Alnylam Pharmaceuticals

Which institutional investors are shorting Alnylam Pharmaceuticals?

As of the most recent reporting period, the following institutional investors, funds, and major shareholders have reported short positions of Alnylam Pharmaceuticals: Bank of America Corp DE, Jefferies Group LLC, Ikarian Capital LLC, Walleye Trading LLC, Parallax Volatility Advisers L.P., Balyasny Asset Management LLC, Boothbay Fund Management LLC, Citadel Advisors LLC, Squarepoint Ops LLC, Bank of America Corp DE, SG3 Management LLC, Credit Suisse AG, Jefferies Group LLC, Nuveen Asset Management LLC, Goldman Sachs Group Inc., PEAK6 Investments LLC, JPMorgan Chase & Co., Simplex Trading LLC, Twin Tree Management LP, Susquehanna International Group LLP, Wolverine Trading LLC, and Cutler Group LP. These positions are disclosed in Form 13F filings with the Securities and Exchange Commission.

Is Alnylam Pharmaceuticals' short interest increasing or decreasing?

Alnylam Pharmaceuticals saw a decline in short interest in September. As of September 30th, there was short interest totaling 4,010,000 shares, a decline of 9.3% from the previous total of 4,420,000 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment.

How does Alnylam Pharmaceuticals' short interest compare to its competitors?

0.00% of Alnylam Pharmaceuticals' shares are currently sold short. Here is how the short interest of companies in the sub-industry of "biotechnology" compare to Alnylam Pharmaceuticals: Amgen Inc. (1.96%), Gilead Sciences, Inc. (0.00%), Regeneron Pharmaceuticals, Inc. (1.76%), Vertex Pharmaceuticals Incorporated (1.97%), Biogen Inc. (1.68%), Seagen Inc. (1.78%), Exact Sciences Co. (0.00%), Repligen Co. (3.29%), Incyte Co. (2.52%), and BioMarin Pharmaceutical Inc. (5.96%).

Which stocks are the most shorted right now?

As of the most recent reporting period, the following stocks had the largest short interest positions: S&P Global Inc. ($7.35 billion), Advanced Micro Devices, Inc. ($6.43 billion), Charter Communications, Inc. ($5.68 billion), Wayfair Inc. ($4.48 billion), Uber Technologies, Inc. ($3.77 billion), Canadian Pacific Railway Limited ($3.73 billion), Palo Alto Networks, Inc. ($3.10 billion), Zoom Video Communications, Inc. ($2.87 billion), Match Group, Inc. ($2.83 billion), and DoorDash, Inc. ($2.54 billion). View all of the most shorted stocks.

What does it mean to sell short Alnylam Pharmaceuticals stock?

Short selling ALNY is an investing strategy that aims to generate trading profit from Alnylam Pharmaceuticals as its price is falling. Alnylam Pharmaceuticals' stock is trading down $5.72 today. To short Alnylam Pharmaceuticals stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that Alnylam Pharmaceuticals will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit.

How does a short squeeze work against Alnylam Pharmaceuticals?

A short squeeze for Alnylam Pharmaceuticals occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of ALNY, which in turn drives the price of the stock up even further.

How often is Alnylam Pharmaceuticals' short interest reported?

Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including ALNY, twice per month. The most recent reporting period available is September, 30 2021.